Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Directorate Change

29 May 2013 07:00

RNS Number : 7347F
Silence Therapeutics PLC
29 May 2013
 



 

Appointment of chief executive and director of corporate development

29th May 2013

Silence Therapeutics plc (AIM: SLN) announces today the appointment of Ali Mortazavi as chief executive and of Annie Cheng as director of corporate development.

Ali Mortazavi joined Silence in August 2012 as director of corporate strategy and since that time has increasingly taken on the mantle of the CEO role. This included overseeing two fundraisings last year to raise £11m for the company and spearheading the £19m placing completed in April 2013. Ali has over 17 years of experience in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm, leaving in 2008. He has extensive experience in small companies and has had significant stakes in UK listed technology / biotech ventures.

Annie Cheng (Annie Jia Huey Cheng), age 37, joins the company after working as a strategy consultant for the Company since October 2012. She has 14 years of experience in the healthcare industry, in equity research and consulting with JP Morgan and boutique investment banks in New York and London.

She has been a director of Visible Value LLP, a biotech consultancy, since December 2011 and of Valor Visible Ltd, its associated business, since October 2012.

There are no other matters to disclose regarding her appointment under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for Companies.

 

Chairman Jerry Randall said: 'Ali brings a wealth of experience in the capital markets as well as small cap companies, and has been instrumental in the development of Silence since he joined. Annie's combination of investor and commercial experience is very valuable.'

 

Silence Therapeutics

Ali Mortazavi, chief executive/Timothy Freeborn, finance director +44 (0)333 988 0140

a.mortazavi@silence-therapeutics.com

t.freeborn@silence-therapeutics.com

 

N+1 Singer

Shaun Dobson/Jenny Wyllie

+44 20 7496 3000

shaun.dobson@n1singer.com

jenny.wyllie@n1singer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUBPAUPWGQR
Date   Source Headline
16th Jan 20132:16 pmRNSHolding(s) in Company
14th Jan 20133:08 pmRNSReplacement - Exercise of warrants
14th Jan 20137:00 amRNSExercise of warrants
2nd Jan 20138:36 amRNSAppointment of Chief Medical Officer
31st Dec 201210:30 amRNSHolding(s) in Company
28th Dec 20127:00 amRNSTotal Voting Rights
6th Dec 20124:22 pmRNSHolding(s) in Company
3rd Dec 20123:12 pmRNSOption exercise
3rd Dec 20121:36 pmRNSHolding(s) in Company
3rd Dec 20121:34 pmRNSHolding(s) in Company
30th Nov 201212:52 pmRNSHolding(s) in Company
30th Nov 20128:05 amRNSHolding(s) in Company
30th Nov 20127:00 amRNSOption Exercise and TVR
28th Nov 20128:33 amRNSDirector/PDMR Shareholding
28th Nov 20127:49 amRNSSubscription and Conversion
21st Nov 20127:00 amRNSProposed Placing
5th Nov 201212:52 pmRNSAdviser Change of Name
5th Nov 201210:24 amPRNUS allows two key patents for Silence Therapeutics
19th Oct 20127:00 amPRNExercise of warrants
15th Oct 20127:01 amPRNExercise of warrants
15th Oct 20127:00 amPRNAppointment of finance director
25th Sep 20127:00 amPRNInterim Results for the Six Months Ended 30 June 2012
20th Sep 20122:59 pmPRNNotice of Results
18th Sep 20127:00 amPRNAppointment of Chief Medical Adviser
10th Sep 201211:12 amPRNTR-1: Notification of Major Interest in Shares
10th Sep 20127:00 amPRNSignificant Pre-clinical Data in Acute Lung Injury
4th Sep 201212:19 pmPRNTR-1: Notification of Major Interest in Shares
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
24th Aug 20122:41 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Aug 20127:00 amPRNCollaboration with MiReven Pty Ltd
20th Aug 20122:44 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
10th Aug 201212:20 pmPRNHolding(s) in Company
6th Aug 201212:21 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
3rd Aug 20125:35 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 20129:00 amPRNAdmission of shares and Board update
31st Jul 201211:26 amPRNNotice of EGM
31st Jul 20127:00 amPRNResults of Open Offer
30th Jul 20125:35 pmPRNHolding(s) in Company
27th Jul 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
24th Jul 20124:35 pmRNSPrice Monitoring Extension
13th Jul 20122:48 pmPRNReplacement - Subscription and Open Offer
12th Jul 20127:00 amPRNSubscription and Open Offer to Raise up to £5.7 million
10th Jul 201210:34 amPRNResponse to press speculation
22nd Jun 20121:35 pmPRNResult of Annual General Meeting
6th Jun 201212:00 pmPRNPhase I data for Atu027 and Potential Fundraising
17th May 20127:00 amPRNNew data from Phase I trial with Atu027
14th May 20127:00 amPRNPublication of 2011 Annual Report and Notice of AGM
3rd May 20127:00 amPRNSilence Therapeutics’ Partner extends agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.